Analytical Data
-
Gene name
BMPR-II
- Application
-
Alternative Names
BMPR-2; BMPR-II; PPH1
-
Species
Human
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13873-1
-
Expression Region
S27-T150
-
Protein Length
Extracellular Domain
-
Molecular Weight
55-70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BMPR-II (Bone Morphogenetic Protein Receptor Type II) is a crucial transmembrane receptor that plays a significant role in the bone morphogenetic protein (BMP) signaling pathway, which is essential for various biological processes, including embryonic development, tissue homeostasis, and bone formation. Mutations or dysfunctions in the BMPR-II gene are linked to serious cardiovascular conditions, particularly heritable pulmonary arterial hypertension (PAH), where abnormal vascular remodeling leads to increased pulmonary artery pressure and associated morbidity. Research into BMPR-II recombinant protein focuses on understanding its structural and functional properties, exploring its role in cellular signaling, and its potential therapeutic applications. Recombinant BMPR-II is being investigated for its ability to restore or mimic endogenous BMPR-II signaling in pathological conditions, offering insights into novel treatment strategies for PAH and other diseases linked to disrupted BMP signaling. Additionally, studies on BMPR-II’s interactions with various ligands and downstream signaling molecules aim to elucidate its mechanism of action, thereby contributing to the development of targeted therapies that could mitigate the effects of BMPR-II deficiencies. As such, BMPR-II recombinant protein serves as a valuable tool in both basic and clinical research, holding promise for advancing our understanding of BMP-related pathways and devising innovative approaches for treating related disorders.
